Company intelligence / Profile preview

Laurantis Pharma

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Laurantis Pharma developed first-in-class products based on proprietary formulations of cis-UCA and gene therapy approaches. Its lead programs included a Phase 2 clinical trial for cis-UCA eye drops in dry eye syndrome. The company also advanced Lymfactin™, an adenoviral VEGF-C gene therapy, into clinical development for secondary lymphedema. In April 2014, Laurantis was acquired by Hermo Pharma and merged into Herantis Pharma Plc.

Therapeutic areas: DermatologyOphthalmologyNephrologyOncology
Modalities: Small molecule (cis-urocanic acid)Gene therapy (adenoviral vector expressing vascular endothelial growth factor C)
Industry: Biotech

Partnerships

Inveni Capital and Helsinki University Funds were investors

Beyond the preview

Go deeper on Laurantis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laurantis Pharma.

Explore the full profile